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Background: New clinical research findings may require clinicians to change their behaviour to provide high-quality
care to people with type 2 diabetes, likely requiring them to change multiple different clinical behaviours. The
present study builds on findings from a UK-wide study of theory-based behavioural and organisational factors
associated with prescribing, advising, and examining consistent with high-quality diabetes care.
Aim: To develop and evaluate the effectiveness and cost of an intervention to improve multiple behaviours in
clinicians involved in delivering high-quality care for type 2 diabetes.
Design/methods: We will conduct a two-armed cluster randomised controlled trial in 44 general practices in the
North East of England to evaluate a theory-based behaviour change intervention. We will target improvement in
six underperformed clinical behaviours highlighted in quality standards for type 2 diabetes: prescribing for hypertension;
prescribing for glycaemic control; providing physical activity advice; providing nutrition advice; providing on-going
education; and ensuring that feet have been examined. The primary outcome will be the proportion of patients
appropriately prescribed and examined (using anonymised computer records), and advised (using anonymous
patient surveys) at 12 months. We will use behaviour change techniques targeting motivational, volitional,
and impulsive factors that we have previously demonstrated to be predictive of multiple health professional
behaviours involved in high-quality type 2 diabetes care. We will also investigate whether the intervention was
delivered as designed (fidelity) by coding audiotaped workshops and interventionist delivery reports, and operated
as hypothesised (process evaluation) by analysing responses to theory-based postal questionnaires. In addition, we
will conduct post-trial qualitative interviews with practice teams to further inform the process evaluation, and a
post-trial economic analysis to estimate the costs of the intervention and cost of service use.
Discussion: Consistent with UK Medical Research Council guidance and building on previous development
research, this pragmatic cluster randomised trial will evaluate the effectiveness of a theory-based complex
intervention focusing on changing multiple clinical behaviours to improve quality of diabetes care.
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Type 2 diabetes is an increasingly prevalent chronic ill-
ness and an important cause of avoidable mortality. The
prevalence in the North East Region of England is esti-
mated at 5.6% (http://www.yhpho.org.uk/resource/view.
aspx?RID=81090) equating to approximately 96 patients
per full time general practitioner. A review of quality of
care studies (including diabetes) in UK primary care
concluded that ‘in almost all studies the process of care
did not reach the standards set out in national guidelines
or set by the researchers themselves’ [1]. A national
audit of diabetes care showed that less than 50% of pa-
tients received all nine key aspects of diabetes care, with
considerable variability across the country [2]. However,
care for people with diabetes has been improving: data
from the UK’s voluntary incentive system for promoting
high-quality care—the Quality and Outcomes Framework
(QOF)—shows that quality scores across the UK are
high, though many indicators are arguably relatively un-
demanding. However, for the most demanding indica-
tors (e.g., relating to tighter levels of HbA1c or blood
pressure control) QOF performance is lower. Some of
this variability likely reflects patient physiology or be-
haviour, but also reflects variable clinician management.
Recognition of quality gaps has led to increased inter-
est in implementation research (the scientific study of
methods to promote the systematic uptake of research
findings into routine clinical practice) over the past
15 years [3,4]. The transfer of research findings into
practice is often slow, leading to gaps in quality of care
[5]. Interventions to improve the quality of care that
patients receive can be effective, but previous studies
provided little theoretical or conceptual rationale for
their choice of intervention [6] and only limited de-
scriptions of the interventions and contextual data [7].
We have argued [8] that a poor understanding of poten-
tial barriers and enablers to implementation limits the
capacity to design appropriately targeted interventions.
The challenge for implementation researchers is to
develop and evaluate a theory-based approach to inter-
vention design that will offer a generalisable framework
for research and support the choice and development of
interventions. The present cluster randomised controlled
trial represents a response to this challenge, building upon
recently completed development work identifying theoret-
ical constructs that consistently predict healthcare profes-
sional behaviour and that are potentially modifiable in an
intervention [9,10].
Evidence base for intervention development to identify
theory: the improving quality in diabetes (iQuaD) study
Results from our recently completed study directly
informs this protocol [9,11]. The ‘improving Quality in
Diabetes’ (iQuaD) study was a national, theory-basedstudy of the structural, organisational and individual
factors associated with the performance of six health-
care professional behaviours involved in managing type
2 diabetes in primary care in the UK. We identified six
clinical behaviours covering a range of clinical activities
(prescribing, non-prescribing), some of which were
challenging (e.g., controlling blood pressure and HbA1c
that was above target despite other drug treatment), and
reflected recommended best practice as described by
national guidelines at the time. Data were collected by
telephone interview to a practice study contact, postal
questionnaire to practice staff, postal questionnaire to
patients, and from patient records. Ninety-nine prac-
tices completed a telephone interview and responded to
baseline questionnaires assessing constructs from a
range of theories. Response rates for all surveys and all
professional groups were >75%. Scores on beliefs about
the six target behaviours were generally consistent with
good practice [9], indicating that care gaps are likely a
function of difficulties in regulating clinical behaviour
in context, rather than knowledge deficits. We also
showed that there is sometimes a discrepancy between
what clinicians report providing and what patients report
receiving [12].
We assessed practice attributes and a wide range of
individually reported measures at baseline; measured
clinical outcomes over the ensuing 12 months, and ad-
ministered a number of measures of clinical behaviour
at baseline and at 12 months. A principal finding of
iQuaD was that there continues to be variability in these
clinical behaviours and most clinical behaviours that we
investigated were not being optimally performed (see
Table 1).
Our results showed that in primary care, individual
healthcare professionals’ beliefs about these behaviours
predicted their clinical behaviour while their perceptions
about their workplace did not; multilevel models also
showed that variability was primarily between individual
clinicians within general practices rather than between
the practices [10]. Based on these findings, an intervention
targeting individuals within organisations rather than
targeting their organisation may be more likely to be
effective.
The present study is directly informed by considerable
theoretical development work accomplished within the
iQuaD study wherein we theorised and tested a model of
healthcare professional behaviour that combined existing
theoretical explanations of behaviour [13]. We initially
tested ‘as originally theorised’ versions of multiple different
individual [10], organisational [14] and stress theories [15],
to investigate to what extent constructs from multiple the-
ories predict six different behaviours in the same sample
of health professionals (enabling direct comparison of
findings across multiple behaviours). The research in
Table 1 Targeted clinical behaviours and evidence of performance from the iQuaD study, and associated NICE quality
standards
iQuaD clinical behaviour targeted Behavioural performance from iQuaD NICE quality standarda
1. Over the past 12 months provided general
education about diabetes for patients with
type 2 diabetes
Received by 73% of patients (via patient survey) QS1 - ‘People with diabetes and/or their carers
receive a structured educational programme
that fulfils the nationally agreed criteria from the
time of diagnosis, with annual review and access
to ongoing education’
2. Over the past 12 months provided advice
about weight management to patients with
type 2 diabetes whose BMI is above a target
of 30 kg/m2 even following previous
management
Received by 51% of people whose BMI was
above a target of 30 kg/m2, even following
previous management (via patient survey)
QS2 - ‘People with diabetes receive personalised
advice on nutrition and physical activity from an
appropriately trained healthcare professional or
as part of a structured educational programme’
3. Over the past 12 months provided advice
about self-management for patients with
type 2 diabetes
Received by 68% of patients (via patient survey) QS3 - ‘People with diabetes participate in annual
care planning which leads to documented
agreed goals and an action plan’
4. Over the past 12 months prescribed
additional therapy for the management of
glycaemic control (HbA1c) in patients with
type 2 diabetes whose HbA1c is higher than
64 mmol/mol (8.0%) despite maximum
dosage of two oral hypoglycaemic drugs
Received by 59% of people whose HbA1c was
higher than 8.0%, despite maximum dosage of
two oral hypoglycaemic drugs (via practice-held
prescribing data)
QS4 - ‘People with diabetes agree with their
healthcare professional a documented
personalised HbA1c target, usually between
48 mmol/mol and 58 mmol/mol (6.5% and
7.5%), and receive an ongoing review of
treatment to minimise hypoglycaemia’
QS5 - ‘People with diabetes agree with their
healthcare professional to start, review and stop
medications to lower blood glucose, blood
pressure and blood lipids in accordance with
NICE guidance’
5. Over the past 12 months prescribe
additional antihypertensive drugs for
patients with type 2 diabetes whose blood
pressure is 5 mmHg above target of
140 mmHg (systolic) or 80 mmHg (diastolic)
even following previous management
Received by 40% whose blood pressure (BP) is
above a target of 140 mm Hg for Systolic BP or
80 mm Hg for Diastolic BP, even following
previous management (via practice-held
prescribing data)
QS5 - ‘People with diabetes agree with their
healthcare professional to start, review and stop
medications to lower blood glucose, blood
pressure and blood lipids in accordance with
NICE guidance’
6. Over the past 12 months examined foot
circulation and sensation in the feet of
patients with type 2 diabetes
Received by 91% of patients (via patient survey) QS10 - ‘People with diabetes at risk of foot
ulceration receive regular review by a foot
protection team in accordance with NICE
guidance’
QS11 - ‘People with diabetes with a foot
problem requiring urgent medical attention are
referred to and treated by a multidisciplinary
foot care team within 24 hours’
aFrom NICE quality standard for diabetes in adults (http://www.nice.org.uk/media/7F8/B2/DiabetesQualityStandard.pdf).
Note. QOF = Quality and Outcomes Framework.
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conducted with different samples of healthcare profes-
sionals [16-19]. In addition, we tested each theory
using multilevel modelling to simultaneously account
for individual and practice-level variability in theoret-
ical constructs and clinical behaviour.
We showed particular constructs within particular be-
havioural theories to be consistently predictive of health-
care professional behaviour, including intention/proximal
goals and self-efficacy (social cognitive theory [20]), post-
intentional factors (action and coping planning [21]), and
habit [22] (learning theory), theories which have a broader
evidence base within psychology [23-25] and implemen-
tation science [26]. We tested organisational theories,
including organisational justice, organisational citizenship,
and team climate, and found that while organisationaljustice factors predicted some clinical behaviours cross-
sectionally [14], none of the organisational-level theories
consistently predicted clinical behaviours at 12 month
follow-up [27].
We also hypothesised a priori how some of these the-
ories might combine. We developed and operationalised
a dual process model of health professional behaviour
that simultaneously tested a sequential reflective process
involving how intention to perform a clinical behaviour
was mediated through post-intentional factors (action
planning, coping planning) alongside a parallel impulsive
process accounting for the degree to which clinicians
behave automatically [13]. We demonstrated that, for
most clinical actions tested, a dual process approach
contributed to understanding how reflective and impul-
sive factors relate to clinical behaviours.
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multiple goal pursuit, investigating how clinicians [28,29]
and other populations [30,31] manage competing and facili-
tating goals and priorities in the time available. This research
demonstrated that goal conflict and facilitation are readily
identified and predictive of clinical and health-related behav-
iours and will further inform the present intervention.
To drive forward further improvements in quality of
care, the UK National Institute for Health and Care
Excellence (NICE) published 13 Quality Standards (QS)
for Type 2 diabetes that cover a broader range of areas
of diabetes care than current QOF indicators. Eight of
these directly relate to primary care and to clinical be-
haviours assessed in the iQuaD study, which suggests
areas in which current care falls short of achieving these
indicators. Table 1 describes the QSs that map onto the
clinical behaviours that we have previously investigated
and which will be targeted for change by the intervention
described in this protocol, as well as rates of performance
of each behaviour and the sources of data we have used to
assess these outcomes.
iQuaD provided an unprecedented opportunity to test
and develop further theory that could inform the design
of an intervention to improve diabetes quality of care.
On the basis of this theoretical development, we will de-
velop, pilot, deliver, and evaluate a theory-based behaviour
change intervention targeting GPs and practice nurses to
promote high-quality diabetes care consistent with NICE
quality standards.
Aims
To conduct a cluster randomised controlled trial to evalu-
ate the effectiveness and costs of a theory-based behaviour
change intervention targeting general practitioners (GPs)
and practice nurses/nurse practitioners, to support im-
provement in the provision of high-quality care for
people with type 2 diabetes.
Objectives
1. Recruit 44 general practices in the North East of
England.
2. Develop the content and decide the method of
delivery of a multi-faceted, targeted, theory-based
intervention to change healthcare professional
practice, targeting six key clinical behaviours that
currently show room for improvement.
3. Deliver the intervention to GPs and nurses in 22
general practices.
4. Collect outcome data on the six behaviours by a
combination of patient survey and computer data
extraction 12 months after intervention delivery.
5. Collect process data on the six behaviours using
semi-structured interviews (analysed qualitatively)and theory-based questionnaires (analysed
quantitatively).
6. Assess the fidelity of delivery of the intervention.
7. Conduct a cost analysis using data on the cost of
delivering the intervention and cost of healthcare
resources used because of the intervention.
Methods
Trial design
The study will be a cluster randomised controlled trial
with the general practice as the unit of randomisation
and analysis to protect against contamination and given
the level at which the primary outcome will be measured.
The intervention will be a multi-level intervention, deliv-
ered to teams but targeting individual-level variables (see
CONSORT checklist in Additional file 1).
Participants
The primary study participants will be general practi-
tioners (irrespective of status), practice nurses/nurse prac-
titioners, and healthcare assistants working in the study
practices actively engaged in providing diabetes care. To
assess the clinical behaviour for processes of care that are
not routinely recorded in patients’ notes, we will also re-
cruit an anonymous random sample of 100 people with
type 2 diabetes registered within each practice, asking
them to report whether they have received particular as-
pects of care.
Inclusion criteria
Practice level: any general practice providing care to
people with type 2 diabetes in the North-East of England.
Clinician level: any general medical practitioner, practice
nurse/nurse practitioner or healthcare assistant involved
in providing care to people with type 2 diabetes in the
practice. Patient level: patients over 18 with type 2
diabetes registered with the practice.
Exclusion criteria
Practice-level: practices included in pilot study. Clinician
level: clinicians who work across multiple different general
practices (e.g., district nurses; to avoid contamination).
Patient level exclusions: patients with type 1 diabetes or
those for whom the primary care team consider it would
be clinically inappropriate (e.g., complex comorbidity,
frailty, major psychiatric problems).
Recruitment
Step one: general practice recruitment
Potential participating clusters (i.e., general practices)
will be invited to participate by research facilitators who
will identify a practice contact as a primary point of con-
tact for the research team. The study research associate
(RA) will also present the study design at local GP
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study RA will contact practices to obtain written practice-
level agreement to participate in the trial in principle and
to subsequently arrange details of attendance of GPs,
nurses and healthcare assistants at the intervention
delivery sessions.Step two: clinician recruitment
Once practices are recruited, the study RA will contact
practices to conduct a telephone interview to identify
practice structure features and all clinicians in the practice
providing care to people with Type 2 diabetes who may be
interested in participating. Each identified clinician will be
provided with a study invitation pack by post via the prac-
tice contact, including a letter of invitation, information
sheet, consent form and baseline questionnaire.Step three: patient recruitment
From our previous study [9], we identified that advising
behaviours are not consistently recorded in patient
notes. We therefore conducted a patient survey to ask
patients to report on whether they had received this care
in the past year. Consistent with this approach, we will
invite a random sample of 100 patients with type 2 dia-
betes from each practice to complete an anonymous
postal questionnaire 12 months after the delivery of the
intervention. Patients with type 2 diabetes will be ran-
domly selected from practice lists by the study contact in
each recruited practice using a random sequence provided
by the study statistician. Patients will be anonymous to the
research team.Study setting
The study will be based in 44 general practices within
the North East region of England.Figure 1 Intervention logic model.Intervention development
The development of the intervention will be consistent
with MRC guidance for the development and evaluation
of complex interventions and is an on-going process that
began with our previous national study of theoretical
predictors of diabetes care (iQuaD). iQuaD represents the
Development phase of the MRC Framework, wherein we
identified and developed theory and modelled process and
outcomes. The present study will involve the feasibility
and piloting domain and the evaluation domain of the
MRC Framework, whilst continuing to involve the devel-
opment process. The intervention will be piloted for feasi-
bility and acceptability, and findings from the pilot will
inform further refinement of the intervention as needed.
The intervention content will be directly informed by
theory-testing and theory-development results from iQuaD,
where we demonstrated that motivational and action
factors accounted for variability in clinical behaviour
better than organisational factors [27]. Influenced by re-
search demonstrating a sequential relationship between
motivational and volitional factors and behaviour
[32,33] and between reflective and impulsive processes
[34,35], we also showed that clinical behaviour can often
best be understood as the consequence of two processes
operating in parallel; one rational, one habitual [13]. On
the basis of these results, our intervention development
will be informed by the logic model presented in Figure 1,
which we have refined to focus on the key motivational
and action factors shown to best explain clinical behav-
iour. This model will serve to guide the selection of recog-
nised behaviour change techniques (BCTs [36]) to target
the behaviour patterns we have found to be associated
with lower rates of high-quality care in our previous study.
We will also investigate the impact of the intervention on
the priority of each behaviour, the extent that other clin-
ical behaviours are perceived to facilitate or conflict with
each target behaviour [28,29] and changes in time spent
on each behaviour. We will aim to change the behaviours
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evidence-based diabetes care) and we will investigate and
pilot optimal methods of delivery tailored to suit the or-
ganisational structure of individual practices (i.e., by
whom, to whom and where). We will subsequently publish
a full description of the intervention development and
content.
Control condition
The control group will be asked to complete baseline
and follow-up process questionnaires, but will not receive
any intervention session. The control group will not be
able to access the intervention materials during the inter-
vention period, but will be provided with access after the
trial is complete.
Intervention fidelity
An intervention fidelity study will be conducted to assess
the validity and replicability of the intervention. This will
cover the five standard elements of design, training, de-
livery (including coding BCTs used in the sessions), re-
ceipt, and enactment [37]. Delivery of the intervention
will be assessed by analysing the transcripts of audio-
tapes of the full intervention for each session as well as
via questionnaire-based facilitator report of delivery
completed after each session.
Primary outcomes
The primary outcomes will be based on behaviours as
measured in our previous study, updated to be consistent
with NICE Quality Standards for Type 2 diabetes. Updates
include necessary minor modifications to the thresholds
(compared to those used in our previous study) in the two
prescribing behaviours (for HbA1c and blood pressure
control) in light of evolving guidance, and the advisingTable 2 Primary outcome measures and data sources
Outcome (clinical behaviours)
1. Provide personalised nutrition advice to patients with type 2 diabetes
BMI is above a target of 30 kg/m2 even following previous management
2. Provide on-going education about diabetes for patients with type 2 dia
3. Provide personalised advice on physical activity for patients with type
diabetes
4. Prescribe additional antihypertensive drugs (i.e., new drug or increased
dosage) for patients with type 2 diabetes with uncomplicated hypertensio
blood pressure is at least 5 mmHg above 140/80 mmHg even following p
management
5. Prescribe additional therapy for the management of glycaemic contr
(HbA1c) in patients with type 2 diabetes whose HbA1c is higher than 58
mol (7.5%) despite maximum dosage on all oral hypoglycaemic drugs
6. Personally ensuring that circulation and sensation in the feet of people wi
diabetes have been examined in the past 12 months, by examining feet
and/or referring them
Note. QOF = Quality and Outcomes Framework.behaviours in light of the specific wording of the NICE
Quality Standards. We will also explore the capacity to
use QOF data as secondary sources of data, depending on
the available indicators at the time of follow-up. Table 2
describes the primary outcomes, and the primary and sec-
ondary sources of data.
Process evaluation
Quantitative
To understand the intervention’s mechanism of change,
we will survey participating clinicians in both groups
prior to intervention delivery and again 12 months later
to measure theoretical constructs targeted by our inter-
vention and changes in these constructs associated with
the intervention [38]. We will assess constructs based on
models and measures from the iQuaD study including
constructs from social cognitive theory (intention, self-
efficacy, outcome expectancies), volitional constructs
(action planning, coping planning) and behavioural auto-
maticity for each of the six targeted clinical behaviours.
In addition, we will also investigate whether the inter-
vention alters perceptions of goal facilitation, goal con-
flict and goal priority between clinical behaviours based
on recently developed short measures [29], as well as
measures of clinicians’ time usage. Finally, given the
team-based nature of primary care diabetes management
we will explore whether the intervention alters any
perceptions of team climate (participation, support for
innovation, vision, and task orientation).
Qualitative
There will be two qualitative components to the study.
First, a preliminary set of interviews will be conducted
with a convenience sample of GPs and nurses to assess
perceived barriers and facilitators to engaging in each ofPrimary data source Secondary data sources
whose Patient survey @ 12 months
(receipt of advice)
Clinician survey @ 12 months;
QOF
betes Patient survey @ 12 months
(receipt of education)
Clinician survey @ 12 months;
QOF
2 Patient survey @ 12 months
(receipt of advice)
Clinician survey @ 12 months;
QOF
n whose
revious
Practice computer prescribing
data @ 12 months
Clinician survey @ 12 months;
patient survey @ 12 months;
QOF
ol
mmol/
Practice computer prescribing
data @ 12 months
Clinician survey @ 12 months;
patient survey @ 12 months;
QOF
th type 2
yourself
Practice computer
management data @
12 months
Clinician survey @ 12 months;
patient survey@ 12 months;
QOF
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help to inform the development of the quantitative ques-
tionnaires. The interviews will also involve assessing
preferences for how interventions might be delivered in
a feasible and accommodating way and findings will
serve to further inform development of intervention
content and delivery. Second, after the delivery of the
intervention we will conduct an interview study with
GPs and nurses in a sample of four practices receiving
the intervention to assess perceived intrapersonal, inter-
personal, contextual barriers and facilitators to engaging
with the intervention sessions themselves, subsequent per-
ceived changes in practice, and usage of the intervention
materials. These interviews will also serve to inform the
intervention fidelity assessment. Given that interviews in-
volve a time burden and may constitute a co-intervention
involving prompting, we will conduct the interviews after
the follow-up outcome data has been collected.
Economic evaluation
The economic evaluation will comprise a cost analysis.
All costs will be expressed in 2012/2013 values. The
costs of delivering the intervention will be collected.
Two main sources will be used to assign costs to health-
care resources [39,40] supplemented when necessary
with unit cost data from other official sources and local
surveys. Drug costs will be taken from the British
National Formulary [41]. Within the trial a questionnaire
at 12-month follow-up of an anonymous random sample
of 100 patients from each practice will be asked to report
on the use of NHS (National Health Service) services and
medications over a twelve-month period. No discounting
will be applied. A simplifying assumption will be made
that the use of all costs and resources occurred at the
beginning of the period. Specifically, the economic
evaluation will involve the following:
1. Assessment of the costs of delivering the
intervention in terms of staff training costs (both
facilitator costs and GP time used in training) and
any increase in the amount of standard patient
education leaflets used by practices.
2. The average cost per patient to the NHS of
medications prescribed in relation to hypertension,
glycaemic control, and weight control. Conditional
on available data, typical medication costs/usage
across the intervention group will be compared to
the general population. Differences between control
and intervention groups will also be explored.
3. Costs of service usage: using self-reported
questionnaires at 12 months from an anonymous
sample of patients with type 2 diabetes from each
participating practice, we will seek information on
the use and NHS cost of community based weightcontrol interventions. We will also seek to use
practice records to assess the annual use of diabetes
related services within practices. We will explore the
use of comparator data that would allow us to
forecast the additional workload that a practice
would face as a result of successfully changing
clinical behaviour and any induced change in patient
uptake of practice based diabetes related services.
Intervention and control groups will be compared,
additionally national level data on service use by
diabetes patients will be utilised for an additional
comparator group.
Sample size
Practice-level: 44 practices. Individual-level: The study is
powered to detect change in the primary outcomes (six
different clinical behaviours) between intervention and
control practices. For advising behaviours, the primary
outcome measure will be patients’ reports of having re-
ceived the specific behaviours. In this respect, a random
sample of 100 patients with type 2 diabetes in each prac-
tice will be surveyed. For prescribing and examining be-
haviours, data will be extracted from the patient computer
records of all patients with type 2 diabetes in each prac-
tice. Based on our previous study an intra-cluster correl-
ation coefficient (ICC) of 0.06 is expected and to detect a
15% absolute improvement in any of our measures of be-
haviour (conservatively calculated as 42.5% to 57.5%) with
80% power and 5% significance, our primary and conser-
vative sample size estimate is that we will need 20 patients
from a total of 40 practices. As this sample size does not
account for any potential loss to follow-up, we will recruit
a further four practices (44 in total). Accordingly, two
groups of 22 practices will provide us with 83.9% power to
detect a 15% improvement in any behavioural outcome.
Our previous study (iQuaD) has demonstrated that this
level of recruitment at the patient level is achievable, as we
received postal outcome data from a mean of 41 patients
per practice (having invited 100) and extracted prescribing
data on all patients with type 2 diabetes in the practice
(from analysing these data we identified that about 20
patients per practice were eligible for the specified pre-
scribing behaviours). Based on our previous study we
anticipate a mean sample size of 40 patients per practice
and will thus have greater power. Assuming 40 practices
(two groups of 20), we would have 89% power to detect
a difference of 15 percentage points (42.5% versus 57.5%)
assuming a type 1 error rate of 5% and an ICC of 0.06;
retaining all 44 practices would increase power to 92%.
Interim analyses and stopping guidelines
There will be no interim analysis for the primary trial
outcomes. We will analyse baseline process evaluation
data from clinician questionnaires after the intervention
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psychometric properties of measures, and exploration of
the association between process variables as a preliminary
test of the theorised process models. This will be con-
ducted by the study statistician without knowledge of
group allocation.
The intervention aims to promote optimal performance
of clinical behaviours that are recommended in policy
documents and clinical practice guidelines and thus
represents a very low risk. Therefore, we have no expli-
cit stopping rules.
Randomisation: sequence generation
The unit of randomisation will be the general practice:
Randomisation will be performed by a statistician inde-
pendent of the study team, using computer-generated
random permuted blocks and will be stratified by practice
size (the only organisation characteristic found to be
related to performance in our previous study, iQuaD).
Random sample of 100 patients within clusters: The
study statistician will provide each practice with a
computer-generated list of random numbers to use for
selecting which patients with type 2 diabetes to send a
survey from their practice diabetes register.
Randomisation: type
Permuted-block randomisation, with practice list size as
the blocking factor; 22 practices will be randomised to
intervention, and 22 to control. The size of the permuted
blocks will vary randomly.
Randomisation: allocation concealment mechanism
Each practice will eventually become aware of their alloca-
tion but allocation will be concealed from them until base-
line process evaluation questionnaires have been returned
to the research team. Within a practice, patients are not
being allocated to alternative treatments so allocation
concealment is not an issue.
Randomisation: implementation
Clusters: NHS North of England Commissioning Support
Unit will be involved in inviting all clusters to participate
prior to randomisation. The study RA will send the study
statistician anonymised practice ID codes and associated
patient list sizes. The study statistician will generate the
random sequence and allocate practices to two separate
dummy-coded groups without knowledge of which group
will receive the intervention; the study statistician will
remain blind to allocation until follow-up data has been
collected. Random allocation of clusters to intervention
or control will take place consecutively as practices are
recruited and until our target sample size (44) is reached.
Patients: The study statistician will generate the random
sequence but will not be involved in the implementationof the randomisation. The statistician will provide each
random number list to the study RA, who will send a ran-
dom number list to the practice contact at each of the 44
practices to be used to select a random sample of 100
patients per practice to be sent questionnaires.
Blinding
Given the nature of the intervention, GPs, nurses and
healthcare assistants will inevitably be aware of their
allocation and thus blinding of participants will not be
possible. Each practice contact will become aware of
allocation. To minimise recruitment bias, random alloca-
tion to intervention and control will take place after
practices are recruited but practices will not be informed
of allocation until after both practices and individual
clinicians are identified and recruited (i.e., not until after
baseline clinician questionnaires are returned completed).
Patients within each practice will remain blind to alloca-
tion. The outcome assessor for data from the practice
computers will be kept blind to the allocation. The prac-
tice contact that will use the random sequence of numbers
to identify the random sample of 100 patients within each
practice invited to complete the patient survey will pos-
sibly not be blind to allocation. Blinding of the full re-
search team is also not possible as intervention practices
will be contacted to arrange the intervention sessions.
However, the study statistician conducting the outcome
analysis will remain blinded to allocation until after the
outcome data have been collected at follow-up.
Materials and procedures
Through the conduct of our previous study (iQuaD) we
have developed and tested many of the instruments and
data collection methods that will be used in the trial de-
scribed in this protocol. The study outcome measures
will be the proportion of patients recorded or reporting
appropriately receiving each of the six study behaviours.
We have successfully measured these behaviours in our
previous study [9].
Outcome measures (patient survey)
We will use a short questionnaire to assess patients’ re-
ports of having received care, assessed 12 months after
the intervention delivery. The three advising behaviours
are not reliably recorded in general practice computer
systems [9], and measures of these will be acquired by a
self-administered patient survey.
Using an anonymous survey we will ask people with
diabetes in the study practices about their experiences of
their clinicians providing advice about nutrition, physical
activity, general education about their diabetes and foot
examination, and their confidence in understanding and
enacting of their diabetes care.
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tionnaires, coded by the research team with their practice
study code and a patient code of 1 – 100 (e.g. 001/001),
and 100 reply paid envelopes. Patients will return their
questionnaires directly to the research team. The practice
will not be aware of which patients have or have not
responded to the questionnaire, giving further protection
to patients’ confidentiality.
We will explore the potential of conducting a second
mailing to the same random sample of patients a month
later to promote a higher response. Patient consent to
participate in the anonymised survey will be assumed by
the receipt of a completed questionnaire.
Outcome measures (computer read codes from patient
electronic records)
Prescribing behaviours and foot examination
The behaviours relating to prescribing (prescribing add-
itional antihypertensive drugs, prescribing additional ther-
apy for managing glycaemic control) and foot examination
are measured by extracting clinical and prescribing data
from general practice computers using electronic queries
developed and used in our previous study. We will study
both the performance of clinical behaviours (measuring
HbA1c, BP, foot checks) and the associated biochemical/
physiological measurement (level of HbA1c; level of BP),
accepting that there will be variability in the latter mea-
sures reflecting patient physiology and health behaviour.
The data will relate to the 12-month period following
intervention delivery and be extracted after month 12.
Data will be extracted for a 24-month period (i.e.,
12 months prior to and 12 months after the month
within which the intervention is delivered). We will thus
account for any seasonal effects in performance of the
target behaviours. The search queries will be sent to
each practice, with written guidelines for how to run
the query. For all registered patients with diabetes the
research nurses will run computer queries to extract
data on the total number of patients with diabetes in
the practice and the number who have had: a foot
check; blood pressure, HbA1c, and weight measured;
level of systolic and diastolic blood pressure, level of
HbA1c, cholesterol and body mass index; and diabetes-
related medication (hypoglycaemic drugs, weight redu-
cing drugs). We will pilot the data extraction procedure
with an experienced NHS performance data manager to
ensure reliability in data extraction.
Quality and outcomes framework data
The QOF is a voluntary annual reward and incentive
programme for all primary care practices in the UK. The
QOF details practice-level performance on a number of
key indicators across organisational and clinical areas
including diabetes. The data are publicly available fromthe NHS Information Centre http://www.ic.nhs.uk/. The
QOF data for diabetes mellitus and practice organisation
will be collected for each participating practice for the
12-month period of QOF data collection best matching
the 12-month period before and again after baseline
questionnaire completion.
Process measures (clinician questionnaire)
We will post a baseline questionnaire prior to delivery of
the intervention and a 12-month follow-up question-
naire to each identified practice contact for distribution
to clinicians identified as involved in providing care to
people with type 2 diabetes along with a postage paid
return envelope. Two reminders will also be sent at
baseline and follow-up to non-respondents to promote a
higher response.
Analysis
Main trial analysis
Practice attributes will be described. The primary analysis
will involve testing, for each behaviour, whether there is a
difference between intervention and control in the propor-
tion of patients in each practice for whom the behaviour
was undertaken during the 12 months following the inter-
vention delivery. Rates of behaviour in intervention and
control practices will be compared using a multilevel re-
gression model taking into account the clustering of pa-
tients within practices. Practice list size will be included
as a covariate given its use as a stratification factor. We
will also consider specialist diabetes clinic and onsite in-
sulin prescription as covariates depending on bivariate
correlations. For the two prescribing behaviours the
rates at which patients received the behaviour prior to
the intervention will also be included as covariates in
the analysis. The main analysis will be ‘intention to
treat’; practices randomised to receive the intervention
will be compared with other practices. A secondary ‘as
treated’ analysis will take into account the uptake of the
intervention in each practice.
In the case that outcome is missing for individual
patients if we have other relevant variables for those
individuals we will impute missing values using the
‘across cluster random-effects logistic regression method’
described by Ma et al. [42]. In the case of missing clusters
no imputation will be undertaken. The potential impact of
missing clusters on the estimated impact of the interven-
tion will be assessed using sensitivity analysis involving a
range of assumptions about the performance of the miss-
ing clusters.
Multiple comparisons
Each of the six individual behaviours will be analysed
separately; for each behaviour, we will generate a 95%
confidence interval for the effect of the intervention.
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error rate of 5%. If we assume that the behaviours are
independent, with six separate tests, the probability that
one or more is significant at the five percent level is
0.265. Thus the effective type 1 error rate is 26.5% rather
than the nominal 5% assumed in the power calculation.
However, the probability of two or more tests being sig-
nificant purely by chance is 0.033. In practice, the behav-
iours and associated tests are not independent but this
figure can be used as a guide. Provided that the inter-
vention is shown to have beneficial effects on at least
two of the clinical behaviours this can be regarded as
evidence that the proposed method can be used to
develop effective interventions.
Additional planned analyses
Secondary trial analysis
For the two prescribing behaviours, we will conduct an
interrupted time series (ITS) analysis to investigate
monthly changes over time between intervention and
control practices, for 12 months prior to the interven-
tion through 12 months post-intervention (accounting
to timing of intervention delivery). We will supplement
this analysis with relevant QOF data in each practice,
using a non-equivalent dependent variables analysis to
further bolster the ITS.
Exploratory analyses
To supplement the individual analyses, a pooled estimate
of effect size will be calculated based on a random effects
approach. A statistical model will be developed in which it
is assumed that the size of the effect will not be the same
for each behaviour but that the effect size varies randomly
about some overall mean. Also, while the trial is designed
and powered to detect changes in clinical behaviour, to
inform future interventions, we will explore whether
changes in clinical behaviour are related to changes in
patient intention, self-efficacy and behaviour as well as
changes in patient physiological outcomes (blood pres-
sure, HbA1c).
Process evaluation analyses
Quantitative: We will use analytical methods we have
previously developed to test for differences between
groups on hypothesised targeted constructs, controlling
for baseline differences [38]. Mediation models will be
used to test whether intervention effects on behaviour
are mediated through the targeted theoretical constructs,
incorporating both sequential reflective and parallel im-
pulsive processes.
Qualitative: Perceived intrapersonal, interpersonal, and
contextual barriers and facilitators to engaging with the
intervention will be coded using a coding frameworkand framework analysis informed by the Theoretical
Domains Framework [43].
Fidelity analysis
Relevant portions of the recordings will be transcribed
and analysed using a checklist of BCTs developed from
the intervention protocol, to code whether the planned
BCTs were actually delivered and whether the duration
of delivery of each BCT changes over the course of the
delivery period and between intervention facilitators. We
will also distribute post-intervention feedback forms.
Receipt of the intervention and enactment of targeted
behaviours will be assessed through brief questionnaires
delivered together with the post-intervention process
evaluation questionnaire. We will also assess post-delivery
facilitator debrief checklists of BCTs presumed to be de-
livered. Analyses will be descriptive and we will assess
inter-rater reliability of BCT coding.
Cost analysis
A post trial economic analysis will estimate the costs of
the intervention and cost of service use. Costs to populate
the model will be based upon questionnaire responses
from practices and patients and will be supplemented with
secondary data such as the British National Formulary for
medication costs where appropriate. Both probabilistic (to
explore the impact of statistical imprecision) and deter-
ministic (to explore other uncertainties and scenarios) will
be estimated. Propensity score matching using parametric
modelling techniques will be used to explore differences
in average cost per patient of prescribing in relation to
hypertension and glycaemic control between the interven-
tion and control group.
Discussion
This multi-site cluster trial reflects on-going development
of an intervention consistent with UK Medical Research
Council guidance on the development and evaluation of
complex interventions. Despite policy initiatives such as
the QOF, there remain gaps in care. The present interven-
tion is novel in its acknowledgement and consideration of
multiple behaviour change in clinicians, building on con-
siderable development work. In so doing, it will address
important and relevant questions concerning the need to
move beyond an isolated focus on changing one behaviour
towards a more comprehensive approach that seeks to not
only change multiple behaviours, but also to understand
the mechanisms underpinning multiple behaviour change.
To achieve this, we propose a comprehensive evaluation
including not only the main trial analysis focusing on
primary endpoints, but also hypothesised pathways/
mechanisms of action using behaviour change techniques;
intervention fidelity to allow clearer understanding of
whether interventions were consistently delivered as
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http://www.implementationscience.com/content/9/1/61designed and if not, why not; theory-based quantitative
process evaluation investigating change in targeted
hypothesised pathways; qualitative investigation of bar-
riers and facilitators to trial participation; and a cost
analysis that will inform scalability (e.g. into continuing
medical education). The fidelity study will be key to the
interpretation of the trial findings and will also identify
where intervention delivery can be improved if necessary.
Such extended evaluation is consistent with forthcoming
MRC guidance on process evaluation.
The study will capture a breadth of key recommended
behaviours in diabetes management including prescribing,
advising, and examining behaviours. While descriptively
involving different types of activities, our intervention will
involve targeting constructs that were consistent predic-
tors across multiple clinical behaviours. We do not have
any pre-conceived hypotheses concerning which or how
many of the six targeted clinical behaviours will change,
though we suggest that a positive trial will be defined as
change in at least two of the six target behaviours. Of the
six behaviours, foot examination was previously shown to
be performed at a relatively high (though not optimal) rate
and thus may be more challenging to show improvement,
though we do still expect to change this behaviour.
The present intervention will focus on using a behaviour
change approach to change the behaviour of individual
clinicians within the practice to improve care and it will
be delivered to primary care practices that will likely
vary in their organisational structures. The trial will
thus provide a test of the merit of a behavioural approach
to changing practice. Overall, the trial will contribute sub-
stantive new knowledge to efforts to improve diabetes
quality improvement efforts as well as new theoretical
knowledge concerning the determinants of behaviour
change and the effects of behaviour change techniques
designed to change these determinants.
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